A Phase 1, Open-Label, Multicenter Study of INCA035784 in Participants With Myeloproliferative Neoplasms
Latest Information Update: 23 Jul 2025
At a glance
- Drugs INCA 035784 (Primary)
- Indications Myeloproliferative disorders
- Focus Adverse reactions
- Sponsors Incyte Corporation
Most Recent Events
- 10 Jul 2025 Status changed from not yet recruiting to recruiting.
- 13 Jun 2025 New trial record